Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN)
CUSIP: 92790C104
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.01 par value per share
- Shares outstanding
- 102,220,000
- Total 13F shares
- 107,824,559
- Share change
- +12,946,317
- Total reported value
- $3,355,130,541
- Put/Call ratio
- 54%
- Price per share
- $31.12
- Number of holders
- 229
- Value change
- +$460,108,019
- Number of buys
- 152
- Number of sells
- 60
Quarterly Holders Quick Answers
What is CUSIP 92790C104?
CUSIP 92790C104 identifies VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92790C104:
Top shareholders of VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC |
13D/G
3/4/5
13F
|
Director, 10%+ Owner · Company |
15%
|
16,025,330
|
$345,826,621 | $0 | 23 Oct 2025 | |
| FMR LLC |
13F
|
Company |
12%
|
12,249,355
|
$264,341,081 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
5.3%
|
5,428,521
|
$117,147,485 | — | 30 Sep 2025 | |
| Deep Track Capital, LP |
13F
|
Company |
5.3%
|
5,380,449
|
$116,110,089 | — | 30 Sep 2025 | |
| Kynam Capital Management, LP |
13F
13D/G
|
Company |
1.5%
from 13D/G
|
4,427,927
|
$95,554,665 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.2%
|
4,331,983
|
$93,484,193 | — | 30 Sep 2025 | |
| VR Adviser, LLC |
13F
|
Company |
3.8%
|
3,882,709
|
$83,788,860 | — | 30 Sep 2025 | |
| Commodore Capital LP |
13D/G
13F
|
Company |
3.9%
|
3,200,000
|
$69,056,000 | -$23,738,000 | 30 Sep 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.8%
|
2,842,925
|
$61,350,322 | — | 30 Sep 2025 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2.6%
|
2,609,353
|
$56,309,838 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.5%
|
2,554,166
|
$55,118,902 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.4%
|
2,418,104
|
$52,184,000 | — | 30 Sep 2025 | |
| Novo Holdings A/S |
13F
|
Company |
2.3%
|
2,380,000
|
$51,360,400 | — | 30 Sep 2025 | |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
— |
4.5%
|
3,575,309
|
$48,373,931 | $0 | 31 Dec 2024 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
2.2%
|
2,212,701
|
$47,750,088 | — | 30 Sep 2025 | |
| Eversept Partners, LP |
13F
|
Company |
1.9%
|
1,924,306
|
$41,526,523 | — | 30 Sep 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.8%
|
1,859,458
|
$40,127,104 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.7%
|
1,766,187
|
$38,120,267 | — | 30 Sep 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.7%
|
1,744,406
|
$37,644,281 | — | 30 Sep 2025 | |
| LOOMIS SAYLES & CO L P |
13F
|
Company |
1.5%
|
1,550,328
|
$33,456,078 | — | 30 Sep 2025 | |
| Frazier Life Sciences Public Fund, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,505,200
|
$31,609,200 | — | 23 Sep 2021 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.4%
|
1,462,400
|
$31,558,592 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.2%
|
1,220,128
|
$26,330,362 | — | 30 Sep 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
1.2%
|
1,201,226
|
$25,922,455 | — | 30 Sep 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
1.1%
|
1,154,487
|
$24,913,829 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
1.1%
|
1,122,532
|
$24,224,240 | — | 30 Sep 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1%
|
1,049,385
|
$22,645,728 | — | 30 Sep 2025 | |
| Vivo Capital, LLC |
13F
|
Company |
0.96%
|
982,576
|
$21,203,990 | — | 30 Sep 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.92%
|
937,467
|
$20,230,538 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.85%
|
869,188
|
$18,757,078 | — | 30 Sep 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.84%
|
860,232
|
$18,563,807 | — | 30 Sep 2025 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.83%
|
851,663
|
$18,378,888 | — | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.8%
|
815,485
|
$17,598,166 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.75%
|
764,562
|
$16,499,248 | — | 30 Sep 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
0.72%
|
736,595
|
$15,895,720 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.62%
|
638,777
|
$13,785,019 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.61%
|
620,862
|
$13,398,202 | — | 30 Sep 2025 | |
| Rosalind Advisors, Inc. |
13F
|
Company |
0.59%
|
600,000
|
$12,948,000 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.58%
|
595,361
|
$12,847,890 | — | 30 Sep 2025 | |
| Yiheng Capital Management, L.P. |
13F
|
Company |
0.49%
|
500,261
|
$10,795,632 | — | 30 Sep 2025 | |
| HighVista Strategies LLC |
13F
|
Company |
0.46%
|
469,335
|
$10,128,249 | — | 30 Sep 2025 | |
| Jonathan Violin |
3/4/5
|
Chief Executive Officer, Director |
—
mixed-class rows
|
720,110
mixed-class rows
|
$10,099,005 | — | 02 Feb 2023 | |
| UBS Group AG |
13F
|
Company |
0.44%
|
447,677
|
$9,660,871 | — | 30 Sep 2025 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.42%
|
432,420
|
$9,331,624 | — | 30 Sep 2025 | |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. |
13F
|
Company |
0.41%
|
423,272
|
$9,134,210 | — | 30 Sep 2025 | |
| PANAGORA ASSET MANAGEMENT INC |
13F
|
Company |
0.37%
|
377,711
|
$8,151,003 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.36%
|
368,599
|
$7,955,000 | — | 30 Sep 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.34%
|
344,084
|
$7,425,333 | — | 30 Sep 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.31%
|
312,759
|
$6,749,339 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.3%
|
309,133
|
$6,671,090 | — | 30 Sep 2025 |
Institutional Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) as of Q4 2025
As of 31 Dec 2025,
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value per share (VRDN) was held by
229 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
107,824,559 shares.
The largest 10 holders included
FMR LLC, BlackRock, Inc., VANGUARD GROUP INC, Bellevue Group AG, Fairmount Funds Management LLC, VR ADVISER, LLC, STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, PERCEPTIVE ADVISORS LLC, and Deep Track Capital, LP.
This page lists
229
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
168
Q4 2025 holders
229
Holder diff
61
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.